

Supplementary material has been published as submitted. It has not been copyedited or typeset by Scandinavian Journal of Urology.

**Supplementary Table 1. Questions used in the semi-structured interview during the pilot testing of the questionnaire.**

|                                                                                                     |
|-----------------------------------------------------------------------------------------------------|
| <b>General questions for the semi-structured interview:</b>                                         |
| 1) Did you find any question difficult to understand?                                               |
| 2) Did you find any question difficult to answer?                                                   |
| 3) Were any questions transgressive/taboo-breaking for you?                                         |
| 4) Were there any questions you missed that you think could be relevant?                            |
| 5) Is the layout good. Is the structure of the questions logical? Is the font size easily readable? |
| 6) Do you have any additional comments about the questionnaire?                                     |
| <b>For each of the treatment-specific questions, the patient was asked:</b>                         |
| a) Is the question easy/difficult to understand?                                                    |
| b) How did you find having to place yourself in one of the answering categories?                    |
| c) Do you have any suggestions on how the question could be phrased better?                         |

**Supplementary table 2: Psychological late effects**

| <b>Characteristic</b>    | <b>Case<br/>N = 2262</b> | <b>Control<br/>N = 4092</b> |
|--------------------------|--------------------------|-----------------------------|
| EORTC-QLQ-C30            |                          |                             |
| Fatigue                  | 22.2 (11.1, 33.3)        | 22.2 (11.1, 33.3)           |
| Insomnia                 | 0 (0, 33.3)              | 0 (0, 33.3)                 |
| EORTC-QLQ-NMIBC24        |                          |                             |
| Future worries           | 25 (8.3, 33.3)           | -                           |
| PRO-CTCAE                |                          |                             |
| Discouraged: Frequency   | 1 (1, 2)                 | 1 (1, 2)                    |
| Discouraged: Severity    | 1 (1, 2)                 | 1 (1, 1)                    |
| Discouraged: Impact      | 1 (1, 1)                 | 1 (1, 1)                    |
| Sad: Frequency           | 1 (1, 2)                 | 1 (1, 2)                    |
| Sad: Severity            | 1 (1, 2)                 | 1 (1, 2)                    |
| Sad: Impact              | 1 (1, 2)                 | 1 (1, 1)                    |
| Concentration: Frequency | 1 (1, 2)                 | 1 (1, 1)                    |
| Concentration: Impact    | 1 (1, 1)                 | 1 (1, 1)                    |
| Memory: Severity         | 1 (1, 2)                 | 1 (1, 2)                    |
| Memory: Impact           | 1 (1, 2)                 | 1 (1, 1)                    |
| Anxious: Frequency       | 1 (1, 1)                 | 1 (1, 1)                    |
| Anxious: Severity        | 1 (1, 1)                 | 1 (1, 1)                    |
| Anxious: Impact          | 1 (1, 1)                 | 1 (1, 1)                    |
| Data from DNPR           |                          |                             |
| Anxiety                  | 5 (<1%)                  | 12 (<1%)                    |
| Depression               | 20 (<1%)                 | 30 (<1%)                    |

\*Median (Q1,Q3), N (%)

**Supplementary table 3: Correlations between EORTC-QLQ-C30 Global Health Scale and symptom-specific items.**

| <b>y</b>                                                                    | <b>x</b>                                         | <b>rho</b> | <b>p</b> | <b>Spearman's</b> |
|-----------------------------------------------------------------------------|--------------------------------------------------|------------|----------|-------------------|
| EORTC-QLQ-C30, replies to the global health scale measuring quality of life | EORTC-QLQ-NMIBC24\$Urinary problems              | -0.38      | <2.2e-16 | Weak              |
|                                                                             | EORTC-QLQ-NMIBC24\$Intravesical therapy symptoms | -0.29      | <2.2e-16 | Weak              |
|                                                                             | ICIQ-MLUTS\$Voiding                              | -0.28      | <2.2e-16 | Weak              |
|                                                                             | ICIQ-MLUTS\$Incontinence                         | -0.27      | <2.2e-16 | Weak              |
|                                                                             | ICIQ-FLUTS\$Voiding                              | -0.20      | <2.2e-16 | Weak              |
|                                                                             | ICIQ-FLUTS\$Incontinence                         | -0.28      | <2.2e-16 | Weak              |
|                                                                             | ICIQ-FLUTS\$Filling                              | -0.35      | <2.2e-16 | Weak              |
|                                                                             | Bladder conditions impact on QoL                 | -0.36      | <2.2e-16 | Weak              |
|                                                                             | Sexual conditions impact on QoL                  | -0.25      | <2.2e-16 | Weak              |
|                                                                             | EORTC-QLQ-SHQ\$sexual satisfaction               | -0.22      | <2.2e-16 | Weak              |
|                                                                             | EORTC-QLQ-SHQ\$Sexual pain                       | -0.09      | <2.2e-16 | Very weak         |
|                                                                             | IIEFscore                                        | 0.28       | <2.2e-16 | Weak              |
|                                                                             | EORTC-QLQ-C30\$Nausea and vomiting               | -0.24      | <2.2e-16 | Weak              |
|                                                                             | EORTC-QLQ-C30\$Appetite loss                     | -0.34      | <2.2e-16 | Weak              |
|                                                                             | EORTC-QLQ-C30\$Constipation                      | -0.25      | <2.2e-16 | Weak              |
|                                                                             | EORTC-QLQ-C30\$Diarrhoea                         | -0.23      | <2.2e-16 | Weak              |
|                                                                             | Gastrointestinal conditions impact on QoL        | -0.31      | <2.2e-16 | Weak              |
|                                                                             | EORTC-QLQ-C30\$Fatigue                           | -0.62      | <2.2e-16 | Strong            |
|                                                                             | EORTC-QLQ-C30\$Insomnia                          | -0.30      | <2.2e-16 | Weak              |
|                                                                             | PRO-CTCAE Q55A (Discouraged, Frequency)          | -0.46      | <2.2e-16 | Moderate          |
|                                                                             | PRO-CTCAE Q55B (Discouraged, Severity)           | -0.46      | <2.2e-16 | Moderate          |
|                                                                             | PRO-CTCAE Q55C (Discouraged, Intensity)          | -0.47      | <2.2e-16 | Moderate          |
|                                                                             | PRO-CTCAE Q56A (Sad, Frequency)                  | -0.45      | <2.2e-16 | Moderate          |

|  |                                           |       |          |          |
|--|-------------------------------------------|-------|----------|----------|
|  | PRO-CTCAE Q56B (Sad, Severity)            | -0.44 | <2.2e-16 | Moderate |
|  | PRO-CTCAE Q56C (Sad, Intensity)           | -0.46 | <2.2e-16 | Moderate |
|  | PRO-CTCAE Q46A (Concentration, Frequency) | -0.44 | <2.2e-16 | Moderate |
|  | PRO-CTCAE Q46B (Concentration, Intensity) | -0.46 | <2.2e-16 | Moderate |
|  | PRO-CTCAE Q47A (Memory, Frequency)        | -0.34 | <2.2e-16 | Weak     |
|  | PRO-CTCAE Q47B (Memory, Intensity)        | -0.37 | <2.2e-16 | Weak     |
|  | PRO-CTCAE Q54A (Anxiety, Frequency)       | -0.35 | <2.2e-16 | Weak     |
|  | PRO-CTCAE Q54B (Anxiety, Severity)        | -0.35 | <2.2e-16 | Weak     |
|  | PRO-CTCAE Q54C (Anxiety, I)               | -0.33 | <2.2e-16 | Weak     |

EORTC = European Organisation for Research and Treatment of Cancer, ICIQ = The International Consultation on Incontinence Questionnaires, LUTS = Lower Urinary Tract Symptoms, MLUTS = Male LUTS, FLUTS = Female LUTS, QoL = Quality of Life,